CLC Number:
| [1] Lumachi F, Brunello A, Roma A, et al. Cancer-induced hypercalcemia[J]. Anticancer Res, 2009, 29(5):1551-1555. [2] Dunford JE. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition[J]. Curr Pharm Des, 2010, 16(27):2961-2969. doi:10.2174/138161210793563617. [3] Teixeira S, Branco L, Fernandes MH, et al. Bisphosphonates and Cancer: A relationship beyond the antiresorptive effects[J]. Mini Rev Med Chem, 2019, 19: 988-998. doi:10.2174/1389557519666190424163044. [4] 段铱, 王迪, 熊晶, 等. 以重度高钙血症为首发症状的成人急性B淋巴细胞白血病1例报道及治疗讨论[J].华中科技大学学报(医学版), 2013, 42(6):741-742. [5] Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy[J]. J Clin Endocrinol Metab, 2014, 99:3144-3152. doi:10.1210/jc.2014-1001. [6] Valdes-Socin H, Almanza MR, Fernandez-Ladreda MT, et al. Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor[J]. Archiv Endocrinol Metab, 2017, 61: 506-509. doi:10.1590/2359-3997000000291. [7] Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options[J]. Ther Clin Risk Manag, 2015,11:1779-1788. doi:10.2147/TCRM.S83681. [8] Asonitis N, Angelousi A, Zafeiris C, et al. Diagnosis, pathophysiology and management of hypercalcemia in malignancy: A review of the literature[J]. Horm Metab Res, 2019, 51(12):770-778. [9] Zagzag J, Hu MI, Fisher SB, et al. Hypercalcemia and cancer: Differential diagnosis and treatment[J]. CA-Cancer J Clin, 2018, 68: 377-386. doi:10.3322/caac.21489. [10] Goldner W. Cancer-related hypercalcemia[J]. J Oncol Pract, 2016, 12, 426-432. doi:10.1200/JOP.2016.011155. [11] Dellay B, Groth M. Emergency management of malignancy-associated hypercalcemia[J]. Adv Emerg Nurs J, 2016, 38(1):15-25. doi:10.1097/TME.0000000000000093. |
| [1] |
YIN Dong-mei1, XU Hong-zhi1, ZHANG Jing-yao1, SUI Xiao-hui1, CUI Bin2, MA Chun-yan2, ZHEN Chang-qing1.
Changes and clinical significances of CD4+T cell subsets in aplastic anemia, myelodysplastic syndromes and acute myeloid leukemia patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 66-70. |
| [2] | WANG Chun-mei1, SHENG Guang-yao1, LU Jie2, ZOU Xiang1, FANGYing-qi1,BAI Song-ting1, XIE Lei1. Interactions between p65 and SMRT by Co-Immunoprecipitation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(10): 51-55. |
| [3] | HAN Liping, FAN Juan, WANG Xin, ZHOU Fanghui, LIU xin, SUI Xiaohui. Expression and clinical relevance of ABCA3 in acute myeloid leukemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(7): 108-111. |
|
||
